Scancell Holdings PLC - Oxford, England-based immunotherapies for treatment of cancer and infectious disease - Non-Executive Director Martin Diggle sells 1.3 million shares via Vulpes Life Sciences Fund at average 25.50 pence, worth about GBP318,750, on Wednesday. Vulpes had sold 400,000 shares on Tuesday. Vulpes now has 116.6 million shares, a 14.3% stake.
Current stock price: 25.40p, down 7.6% Friday
Year-to-date change: up 81%
By Tom Waite; firstname.lastname@example.org
Copyright 2021 Alliance News Limited. All Rights Reserved.